Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Duke Researchers Create a Type 1, Type 2 Lupus Disease Model

Catherine Kolonko  |  Issue: October 2020  |  October 20, 2020

Dr. Pisetsky photo

Dr. Pisetsky

In the view of these researchers, lupus is not confounded by such conditions as fatigue or fibromyalgia, they are part of it, according to Dr. Pisetsky. Thus, they created a scheme that includes them as a fundamental aspect of the disease.

“In a sense, we are repositioning where we place these symptoms in the scheme of disease, but I think the importance is to recognize that they are really part of lupus,” he says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The disease model proposed by the Duke team includes symptoms “in a more unified way,” incorporating as essential features of lupus those conditions that are typically considered comorbidities. It helps get around the problem when a patient says “my lupus is active” but lab results don’t show it, says Dr. Pisetsky.

The collaboration of lupus researchers and clinicians at Duke came about by listening to patients speak about their problems and acknowledging that very often their symptoms were not considered disease activity even though they posed major problems for the patient.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“That led us to this idea that these symptoms, what we now call type 2, are very much part of lupus,” says Dr. Pisetsky. “They’re not just incidental. They’re not coincidental. They are part of lupus, but they do not easily fit into the usual scheme—looking at disease activity or looking at damage.

“What we did is to try to come up with a model that incorporates both types, signs and symptoms in a common framework to evaluate patients.”

Type 1 & Type 2 Mix

It is not unusual for lupus patients to experience symptoms that fall into both categories or vary between the two types at different times of active disease, explains Dr. Pisetsky.

“The likelihood, and what our data suggest, is that patients have mixtures of symptoms; some have a significant number of type 1 problems but don’t have very many type 2. Other patients have many more type 2 issues, but don’t have a lot of type 1,” says Dr. Pisetsky.

A clinical evaluation can identify whether a patient is one type or the other, or has mixed activity from both types.

“For example, a patient with SLE may have low disease activity or even disease in remission in terms of type 1 manifestations and associated biomarkers; nevertheless, that patient may experience severe type 2 manifestations and be limited by unrelenting pain and fatigue,” states the article.

Improve Communication & Therapy

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:fatiguelupus disease modellupus subtypesSLE Resource Center

Related Articles

    7 Tools to Identify Depression

    August 1, 2014

    Why screening for depressive symptoms in patients with arthritis is needed

    Duke Researchers Create a Type 1, Type 2 Lupus Disease Model

    November 29, 2022

    A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to cate­gorize two main groups of symptoms into type 1, typically…

    Depression in Rheumatoid Arthritis

    November 1, 2012

    Examining the psychological and health-related comorbidities of rheumatoid arthritis patients with depression

    Lupus often presents with a butterfly rash.

    Top 12: Research in Systemic Lupus Erythematosus at a Glance

    November 18, 2021

    Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences